论文部分内容阅读
对中药肝乐Ⅰ,Ⅱ号方进行实验研究,探讨其是否有抗癌作用及其药理作用。方法所用中药复方肝乐Ⅰ号和Ⅱ号的浓度,每100ml 相当生药200g,实验方法按1978年抗肿瘤药物体内筛选规程进行,瘤株为小鼠肝癌腹水型(HAC)、肝癌实体型((HAS)、艾氏腹水癌(ECA)等。选择10天左右,肿瘤生长旺盛的瘤源动物小白鼠,腹腔或皮下接种10~7个瘤细胞/只,药物于接种后24小时开始灌胃或腹腔给药7～10天。比较治疗组与对照组的实体瘤平均瘤重,计算肿瘤抑制率。腹水癌比较两组的平均生存时间,并进行统计学处理。结果两方对 HAC、HAS 瘤株无抗肿瘤作用。肝乐Ⅰ号抑瘤率为3.1%,Ⅱ号为18.5%。也选用了ECA 动物瘤株,证明两方均无生命延长作用。本实验
Experiments were conducted on traditional Chinese herbal medicines Ganle I, II and its anticancer effect and its pharmacological effects were explored. The concentration of Chinese Herbal Compound Liver I and II used in this method was 200g per 100ml of crude drug. The experimental method was based on the 1978 antitumor drug in vivo screening protocol. The tumor strain was mouse liver ascites type (HAC), liver cancer solid type (( HAS), Ehrlich ascites carcinoma (ECA), etc. A tumor-producing animal mouse whose tumor growth was vigorous for about 10 days was inoculated intraperitoneally or subcutaneously with 10 to 7 tumor cells per mouse, and the drug was intragastrically administered 24 hours after inoculation or After intraperitoneal administration for 7 to 10 days, the average tumor weights of the solid tumors were compared between the treatment group and the control group to calculate the tumor inhibition rate.The average survival time of the ascitic fluid cancers was compared between the two groups, and statistical analysis was performed.Results Both sides showed HAC and HAS tumors. The strain had no anti-tumor effect, and the tumor inhibition rate of Ganle I was 3.1%, and that of II was 18.5%, and ECA animal tumor strains were also selected to prove that both of them had no prolongation of life.